This page lists the SEC filings reported by Novo Holdings A/S.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13D/A | 2024-03-28 | Novo Holdings A/S | SPRUCE BIOSCIENCES, INC. | 1,656,000 | 3.9% | EDGAR |
| SC 13D/A | 2024-03-25 | Novo Holdings A/S | SPRUCE BIOSCIENCES, INC. | 2,756,000 | 6.4% | EDGAR |
| SC 13D/A | 2024-03-20 | Novo Holdings A/S | SPRUCE BIOSCIENCES, INC. | 4,671,021 | 10.9% | EDGAR |
| SC 13D/A | 2024-03-18 | Novo Holdings A/S | SPRUCE BIOSCIENCES, INC. | 6,466,020 | 15.1% | EDGAR |
| SC 13D/A | 2024-03-07 | Novo Holdings A/S | LAVA Therapeutics NV | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Novo Holdings A/S | Evotec SE | 14,931,858 | 8.4% | EDGAR |
| SC 13D/A | 2024-02-13 | Novo Holdings A/S | IO Biotech, Inc. | 7,557,393 | 11.1% | EDGAR |
| SC 13D/A | 2024-01-25 | Novo Holdings A/S | Edgewise Therapeutics, Inc. | 6,344,430 | 7.4% | EDGAR |
| SC 13G/A | 2024-01-02 | Novo Holdings A/S | Rallybio Corp | 1,767,861 | 4.7% | EDGAR |
| SC 13D/A | 2023-12-15 | Novo Holdings A/S | Reneo Pharmaceuticals, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2023-12-15 | Novo Holdings A/S | Lexeo Therapeutics, Inc. | 1,307,829 | 4.9% | EDGAR |
| SC 13G | 2023-11-24 | Novo Holdings A/S | Lexeo Therapeutics, Inc. | 1,294,053 | 5.1% | EDGAR |
| SC 13D/A | 2023-11-09 | Novo Holdings A/S | LAVA Therapeutics NV | 1,878,194 | 7.1% | EDGAR |
| SC 13D/A | 2023-08-11 | Novo Holdings A/S | IO Biotech, Inc. | 8,216,202 | 12.0% | EDGAR |
| SC 13D/A | 2023-08-03 | Novo Holdings A/S | Cyteir Therapeutics, Inc. | 1,547,136 | 4.4% | EDGAR |
| SC 13D/A | 2023-07-26 | Novo Holdings A/S | Cyteir Therapeutics, Inc. | 3,072,136 | 8.7% | EDGAR |
| SC 13D/A | 2023-06-28 | Novo Holdings A/S | Edgewise Therapeutics, Inc. | 6,071,703 | 9.6% | EDGAR |
| SC 13G/A | 2023-06-28 | Novo Holdings A/S | Galera Therapeutics, Inc. | 2,100,000 | 4.9% | EDGAR |
| SC 13G/A | 2023-06-28 | Novo Holdings A/S | Disc Medicine, Inc. | 1,090,772 | 4.8% | EDGAR |
| SC 13D/A | 2023-06-06 | Novo Holdings A/S | LAVA Therapeutics NV | 2,400,000 | 9.1% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.